There are currently 603 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, Virginia Cancer Institute and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
NCT04763356
Recruiting
This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571
Recruiting
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia
Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
Recruiting
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT06237179
Recruiting
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance \[6MWD\]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.
Gender:
MALE
Ages:
Between 40 years and 85 years
Trial Updated:
02/26/2025
Locations: Richmond Veterans Affairs Medical Center, Richmond, Virginia +1 locations
Conditions: Prostate Cancer, Supportive Care
Register for Updates
Study of ATX-01 in Participants with DM1
NCT06300307
Recruiting
The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/26/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Myotonic Dystrophy 1
Register for Updates
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
NCT05488340
Recruiting
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an activ... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Research Site 127, Richmond, Virginia
Conditions: Urinary Tract Infections
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth, Richmond, Virginia
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lung Cancer
Register for Updates
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06370000
Recruiting
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Acute Myeloid Leukemia
Register for Updates
Anti-Inflammatory Lifestyle Intervention for Emerging Adult Cancer Survivors
NCT06442397
Recruiting
To test the feasibility and acceptability of AILI and associated research procedures among emerging adult cancer survivors (EACS, N=16) age 18-29.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, School of Medicine, Richmond, Virginia
Conditions: Survivorship
Register for Updates
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
NCT06731413
Recruiting
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Register for Updates
Immune Registry for BK in Kidney Transplant Recipients
NCT06538961
Recruiting
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection and infections in KT recipients. BK virus is an important clinical infection affecting the post-transplant outcomes in KT recipients. BK nephropathy can affect 8-15% of patients after KT causing acute kidney injury, increased risk of rejection and fibrosis leading to add... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: BK Virus Infection, Kidney Transplant; Complications
Register for Updates